The overall goal of the Pharmacology and Analytical Center Facility is to provide the broad base of sophistical analytical equipment and expertise in pharmacology and medicinal chemistry required for preclinical and clinical investigations of anti-cancer drugs and related therapies. This goal will be accomplished by focusing on three aims. First, the Pharmacology and Analytical Center Facility will enable expanded analytical support for basic and clinical scientists at The University of Texas M.D. Anderson Cancer Center. This support will include access to instruments for nuclear magnetic resonance (NMR), liquid chromatography (LC)/mass spectrometry (MS), gas chromatography (GC), GC/MS, and high- performance liquid chromatography (HPLC). Support will also include assistance with the verification of structural identify, purification, and determination of stability of drugs and drug metabolites, as well as assistance with developing assays, solving proof-of-identity problems, and developing validation procedures. Second, scientists running the Pharmacology and Analytical Center Facility will provide a resource for investigators seeking pharmacokinetic and pharmacodynamic information on specific compounds and knowledge off how to best use such information for optimal protocol design, dose adjustments to increase efficacy or decrease toxicity, and similar clinical problems. Finally, the Pharmacology and Analytical Center Facility will provide a pharmacology resource for information about and techniques for studying nucleic acid components, such as bases, nucleosides, nucleotides, and oligonucleotides. This services will also include quantitation of the radioactivity associated with proteins, and Betascope and radiometric flow analytical instrumentation will be available. The analytical instruments of the Pharmacology and Analytical Center Facility are conveniently housed on the same (seventh) floor of M.D. Anderson Cancer Center in laboratories run by Director Robert Newman and co-directors William Plunkett, Timothy Madden, and David Farquhar. The equipment and analytical support to be provided by the facility are deemed critical for the success of many of the disease site- and them-specific programs proposed in this application. Formation of the Pharmacology and Analytical Center Facility will augment the ability of M.D. Anderson investigators to collaborate on studies involving pharmacologic analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S2
Application #
6506690
Study Section
Project Start
2001-09-28
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477

Showing the most recent 10 out of 12418 publications